- Mithra grants exclusive license to Megalabs for commercialization of its vaginal contraceptive ring in Mexico
- Strengthening of the commercial presence in Latin and South America thanks to this second contract with Megalabs
- Myring™ licenses granted to industry leaders in 35 countries, including the world’s three largest markets
Liege, Belgium, 14 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement (LSA) with Megalabs for the commercialization of its hormonal contraceptive ring Myring™ in Mexico. Based in Uruguay, Megalabs develops a wide range of market-leading pharmaceutical products in twenty Latin American countries.